Acadia Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Acadia Pharmaceuticals Reports Strong 2025 Sales, Pipeline Advances Amid EU Regulatory Setback
Acadia Pharmaceuticals reported net product sales of $1.07 billion in 2025, driven by growth in NUPLAZID and DAYBUE, despite a negative trend vote for DAYBUE's EU approval.
NASDAQ
Acadia Pharmaceuticals' 10-K filing summarizes the company's 2024 performance, strategic initiatives, and key risks.
NASDAQ
Acadia Pharmaceuticals Inc. demonstrates significant progress in 2023 with increased product sales and advancements in its clinical pipeline, as detailed in its annual 10-K filing.